Biosimilars and Generic Targeted Therapy Drugs: — What They Are

Yes, within the meaning of what regulatory approval requires. A biosimilar cannot be prescribed in India or most other countries unless it has been shown to have no clinically meaningful differences from the original in safety, purity, and effectiveness. That comparison is made through laboratory studies, animal studies, and clinical trials in people. The CDSCO, WHO, EMA, and FDA all apply this standard. Being approved as a biosimilar is not a lower bar — it is a different bar, applied to a genuinely more complex type of medicine.

Your oncologist and treating team should tell you what medicine you are being prescribed and why. If you are starting a biosimilar version of a medicine you previously received as the original, that is a decision your team should explain. In some settings, pharmacists are permitted to substitute a biosimilar for the original without a separate consultation — this practice varies by hospital and by state. It is reasonable to ask at each visit whether your prescription has changed, and if so, what changed and why.

The cost of testing a biosimilar is real, but far lower than the cost of discovering and proving the original medicine from scratch. The original manufacturer spent years and a large amount of money demonstrating that the drug worked in the first place. A biosimilar manufacturer builds on that established science — they do not repeat early discovery, initial safety work in healthy volunteers, or the large trials that proved the drug works. The savings come from not having to re-establish what is already known, not from skipping regulatory steps.

The regulatory requirement is that the side-effect profile is not meaningfully different from the original. Clinical trial data comparing the two are part of what regulators review before approving a biosimilar. In practice, reported side effects are expected to be the same because the mechanism of action and biological activity must be shown to be equivalent. If you notice something unexpected after switching from one version to another, tell your oncology team — reporting it is important for your care and for the ongoing pharmacovigilance that regulators require after approval.

A generic is an exact chemical copy of a small-molecule drug. Several oral targeted therapy tablets used in cancer — in some lung, kidney, and blood cancers — are small-molecule medicines that have approved generic versions. A biosimilar is a version of a biological medicine, usually a large complex protein made in living cells, shown to be highly similar but not an exact copy. The approval process for a biosimilar is more extensive than for a generic. Both require regulatory clearance before reaching patients.

Yes. The CDSCO has a specific approval pathway for biosimilars — called Similar Biologics — in place since 2016. Several biosimilars relevant to cancer treatment have been approved under this pathway, including versions of medicines used in breast cancer and other tumour types. Indian manufacturers are also significant producers of biosimilars exported to other countries. Approval by the CDSCO means the medicine has met the regulator's requirements for safety and effectiveness before reaching patients.

Regulatory approval means both are expected to work the same way. Major oncology bodies — including NCCN, ASCO, and ESMO — treat an approved biosimilar as clinically interchangeable with the original for most treatment decisions. Where it may matter is if you have previously had a reaction to a specific formulation, or if there is a documented clinical reason your oncologist wants you on a particular version. If you have concerns, ask your oncologist to explain the reasoning behind the prescription you have been given. That is a reasonable question.

The medicine will have a different brand name from the original, though the non-proprietary name will include the reference drug's name — for example, a biosimilar of trastuzumab will have trastuzumab in its name. Your prescription, your treatment plan, or the label on the infusion bag should identify it. If you are unsure, ask the nurse or pharmacist before your treatment begins. You are entitled to know exactly what medicine you are receiving, and asking is the right thing to do.